The healthcare investment industry is putting money into some really exciting startups and early-stage ventures over the past few years. One hedge fund manager in this industry, Jacob Gottlieb, MD, CFA, PRMIA, is one of these investors with hid company Altium Capital. At this firm, based in New York City, he invests exclusively in healthcare companies that are coming up with meaningful medical treatments.
A few of the companies that Jacob Gottlieb has decided to invest in are Oragenics, Oramed Pharmaceuticals, and Amarin Corporation. He took a 5.61 percent stake in Oramed Pharmaceuticals which created a treatment for diabetes that is taken orally rather than the traditional method of using a needle. They have three treatments which are an analog capsule, a Glucagon-like peptide-1, and an insulin capsule.
Amarin, which Jacob Gottlieb invested in as his second investment at newly formed Altium Capital, is a company based in Dublin, Ireland. They are creating drugs that will help to improve cardiovascular health. They are combining the benefits of polyunsaturated fatty acids with their expertise in lipid science. They have one drug now approved by the FDA called Vascepa which provides prescription strength omega-3 fatty acids. This drug went on the market in 2012.
Jacob Gottlieb says he invested in Oragenics because he believes they will become a trendsetter when it comes to creating novel antibiotics to fight infectious diseases. They engage in what is known as Replacement Therapy which involves replacing the harmful bacteria in a body with good bacteria. This results in a healthier body and they are using it to develop a treatment for oral mucositis.
Jacob Gottlieb is pretty happy with his initial three investments at his latest hedge fund and is looking forward to investing in more exciting healthcare firms. He has been in the hedge fund industry since 2001.